St. Jude, Boston Scientific tout renal denervation results; Infraredx partners up with Philips;

@FierceMedDev: DOD agency commits $70M to develop brain-monitoring implant. Item | Follow @FierceMedDev

@MarkHFierce: Apollo Endosurgery, a 2012 Fierce 15 winner, aims for big growth by snatching up Allergan's obesity device business. Story | Follow @MarkHFierce

@MichaelGFierce: ICYMI: A blog post from the FDA late last week highlighted the agency's efforts to regulate nanotechnology. Blog | Follow @MichaelGFierce

> St. Jude Medical ($STJ) said studies of its EnligHTN renal denervation system show that patients still have a sustained reduction in blood pressure 18 months after their initial procedure. Item

> Infraredx has signed a deal with Philips ($PHG) under which the multinational giant will market its TVC vascular imaging system alongside its own X-ray devices in North America and Europe. News

> South Dakota economic development officials are trying to recruit medical device companies to the state. Story

> Vention Medical, a company that offers design, engineering and manufacturing services for medical devices and components, is snatching up Fast Forward Medical, a Minnesota startup that designs and manufacturers catheters. Item

> Boston Scientific ($BSX) revealed that its Vessix renal denervation system sustained a 29.6 mmHg reduction in systolic blood pressure at 12 months. More

> Alere ($ALR) boosted its revenue by 9% to $753.9 million last quarter, but the weight of its recent acquisitions deepened its net loss by almost 270% to $24.8 million. Results

> Italy's Sorin has fully recovered from the impact of a 2012 earthquake. The cardiac device company said it generated substantially higher 2013 third quarter revenue and adjusted net profit compared to the same period a year ago. Item

Biotech News

@FierceBiotech: Popular on FierceCRO.com: InVentiv opens U.K. hub as EU demand climbs. Article | Follow @FierceBiotech

@JohnCFierce: The ax drops at troubled Merck as big restructuring gets underway. Story | Follow @JohnCFierce

@DamianFierce: Ex-Calistoga chief Gallagher joins VC Frazier Healthcare to steer biotech bets. News | Follow @DamianFierce

> Calithera grabs $35M round to fund first slate of cancer drug studies. More

> Eli Lilly partners with Pfizer on its high-risk PhIII pain med tanezumab. News

Pharma News

@FiercePharma: isn't getting post-marketing data on fast-tracked drugs, per JAMA. Required studies undone or unreported. JAMA report | Follow @FiercePharma

@CarlyHFierce: Biogen's Tecfidera drives rosy Q3 results, higher forecast. ICYMI yesterday | Follow @CarlyHFierce

> Vertex to slash 370 jobs in shift away from hep C drug. News

> Sunk by generics, Pfizer clings to emerging markets, cancer meds. Article

Pharma Manufacturing News

@EricPFierce: What drugs are up for grabs by generic makers next year? Here's the FiercePharma list of 2014 patent losses. | Follow @EricPFierce

> Wockhardt profits crater after U.S., U.K. plant bans. More

> Manufacturing glitch leaves Novo insulin cartridges with bad fills. Report

> Gilead expanding facility that makes highly anticipated hep C drug. Story

> India's plan to inspect China plants stalled. Article

Biotech Research News

@EmilyMFierce: I took a look at 5 promising preclinical drug programs across industry/academia for this latest report. Feature | Follow @EmilyMFierce

> Fast-acting antidepressants discovered. Report

> New obstacle found in search for HIV/AIDS cure. Item

> Certain microRNAs might be viable Alzheimer's targets. Article

> CytomX 'probody' kills pancreatic cancer cells, leaves healthy tissue intact. Story

Suggested Articles

The randomized, blinded study showed statistically significant improvements in assessments of inattention and brain activity.

U.K.-based surgery robot developer CMR Surgical has begun rolling out its Versius platform to the NHS, completing its first procedures in Europe.

The former Fierce 15 winner’s SuperMap program was cleared to guide electrophysiologists in the treatment of stable and transient arrhythmias.